Depression after lung transplantation: Causes and treatment

Lung

Volumn 185, Issue 2, 2007, Pages 55-65

  Fusar Poli, P ^a   Lazzaretti, M ^a   Ceruti, M ^a   Hobson, R ^b   Petrouska, K ^a   Cortesi, M ^a   Pozzi, E ^a   Politi, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antidepressants; Depression; Lung transplantation; Quality of life

Indexed keywords

CITALOPRAM; CYCLOSPORIN; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR;

AGE; COPING BEHAVIOR; DEPRESSION; EMBASE; FUNCTIONAL ASSESSMENT; GENDER; HUMAN; LUNG TRANSPLANTATION; MEDLINE; METHODOLOGY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; PSYCINFO; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STRESS; TIME SERIES ANALYSIS;

ADAPTATION, PSYCHOLOGICAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COGNITIVE THERAPY; DEPRESSION; HUMANS; LUNG TRANSPLANTATION; MIANSERIN; PSYCHOLOGY; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS;

EID: 34147157740     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-006-0093-1     Document Type: Review

References (70)

1. Allan R, Scheidt S (1998) Group psychotherapy for patients with coronary heart disease. Int J Group Psychother 48:187-214
2. Anayanwu A, McGuire A, Rodgers C (2001) Assessment for quality of life in lung transplantation using a simple generic tool. Thorax 56:218-222
3. Anderson I (2001) Meta analytical studies on new antidepressants. Br Med Bull 57:161-178
4. Anttila SA, Leinonen EV (2001) A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7(3):249-264
5. Barefoot J, Schroll M (1996) Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 93:1976-1980
6. Brown ES, Suppes T (1998) Mood symptoms during corticosteroid therapy: a review. Harv Rev Psychiatry 5(5):239-246
7. Burggraf G (1997) Are psychotropic drugs at therapeutic levels a concern for cardiologists? Can J Cardiol 13(1):75-80
8. Caine N, Sharples LD, Dennis C, Higenbottam TW, Wallwork J (1996) Measurement of health-related quality of life before and after heart-lung transplantation. J Heart Lung Transplant 15(10):1047-1058
9. Campana C, Regazzi M, Buggia I (1996) Clinically significant drug interactions with cyclosporine. An update. Clin Pharmacokinet 30(2):141-179
10. Chacko R, Harper R, Kunik M (1996) Relationship of psychiatric morbidity and psychosocial factors in organ transplant candidates. Psychosomatics 37(2):100
11. Cohen L, Littlefield C, Kelly P (1998) Predictors of quality of life and adjustment after lung transplantation. Chest 113:633-644
12. Craven JL, Bright J, Dear CL (1990) Psychiatric, psychosocial, and rehabilitative aspects of lung transplantation. Clin Chest Med 11(2):247-257
13. Crone C, Gabriel G (2004) Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharm 43(6):361-394
14. Daughton DM, James Fix A, Kass I, Patil KD (1984) Three-year survival rates of pulmonary rehabilitation patients with chronic obstructive pulmonary disease. J Natl Med Assoc 76(3):265-268
15. De Vito Dabbs A, Dew MA, Stilley CS, et al. (2003) Psychosocial vulnerability, physical symptoms and physical impairment after lung and heart-lung transplantation. J Heart Lung Transplant 22(11):1268-1275
16. Dew M (1998) Psychiatric disorders in the context of physical illness. In: Dohrenwend BP (ed) Adversity, stress and psychopathology. Oxford University Press, New York, pp 177-218
17. Dobbels F, Vanhaecke J, Desmyttere A (2005) Prevalence and correlates of pretransplant nonadherence with medication in heart, liver and lung transplantation. Transplantation 79:1588-1595
18. Ernst E (2002) St. John's wort supplements endanger the success of organ transplantation. Arch Gen Surg 137:316-319
19. Ernst E, Pittler M, Stevinson C (2000) Risks associated with complementary therapies. In: Science E (ed) Meyler's side effects of drugs, 14th ed., Elsevier, Amsterdam, pp 1649-1681
20. Fusar-Poli P, Martinelli V, Klersy C, et al. (2005) Depression and quality of life in patients living 10 to 18 years after heart transplantation. J Heart Lung Transplant 24:2269-2278
21. George CF (2000) Perspectives on the management of insomnia in patients with chronic respiratory disorders. Sleep 23 Suppl 1:S31-S35; discussion S36-S38
22. Goetzmann L, Scheuer E, Naef R, et al. (2005) Psychosocial situation and physical health in 50 patients > 1 year after lung transplantation. Chest 127(1):166-170
23. Hammemess P, Basch E, Ulbrischt C (2003) St. John's wort: a systematic review of adverse effects and drug interactions dor the consultation psychiatrist. Psychosomatics 44:271-282
24. Harvey A, Preskorn S (1996) Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol 16(5):345-355
25. Ibister G, Bowe S, Dawson A (1996) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Int Clin Psychopharmacol 11(1):35-40
26. Irani S, Mahler C, Goetzmann L, Russi EW, Boehler A (2006) Lung transplant recipients holding companion animals: impact on physical health and quality of life. Am J Transplant 6(2):404-411
27. Jayaram G, Casimir A (2005) Major depression and the use of electroconvulsive therapy (ECT) in lung transplant recipients. Psychosomatics 46(3):244-249
28. Jonas B, Mussolino M (2000) Symptoms of depression as a prospective risk factor for stroke. Psychosom Med 62:463-471
29. Kugler C, Fischer S, Gottlieb J, et al. (2005) Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant 24(12):2262-2268
30. Lanuza D, Lefaiver C, McCabe M (2000) Prospective study of functional status and quality of life before and after lung transplantation. Chest 118:115-122
31. Limbos MM, Chan CK, Kesten S (1997) Quality of life in female lung transplant candidates and recipients. Chest 112(5):1165-1174
32. Limbos MM, Joyce DP, Chan CK, Kesten S (2000) Psychological functioning and quality of life in lung transplant candidates and recipients. Chest 118(2):408-416
33. Littlefield C (1995) Psychological treatment of patients with end-stage pulmonary disease. Monaldi Arch Chest Dis 50(1):58-61
34. Littlefield C, Abbey S, Fiducia D, et al. (1996) Quality of life following transplantation of the heart, liver, and lungs. Gen Hosp Psychiatry 18(6 Suppl):36S-47S
35. Markowitz J, Gill H, Hunt N (1998) Lack of antidepressant-cyclosporine pharmacokinetic interactions. J Clin Psychopharmacol 18(1):91-93
36. Martensson J, Dracup K, Canary C, Fridlund B (2003) Living with heart failure: depression and quality of life in patients and spouses. J Heart Lung Transplant 22(4):460-467
37. Matthees BJ, Anantachoti P, Kreitzer MJ, et al. (2001) Use of complementary therapies, adherence, and quality of life in lung transplant recipients. Heart Lung 30(4):258-268
38. Mayou R, Gill D, Thompson D (2000) Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 62:212-219
39. Morganroth J, Goin J (1991) Quinidine-related mortality in the short to medium term treatment of ventricular arrhythmias. Circulation 84:1977-1991
40. Murray J (2000) Cardiac disorders and antidepressant medications. J Psychol 134(2):162-168
41. Musselman D, Evans D, Nemeroff C (1998) The relationship of depression to cardiovascular diseases. Arch Gen Psychiatry 55:580-592
42. Parekh PI, Blumenthal JA, Babyak MA, et al. (2003) Psychiatric disorder and quality of life in patients awaiting lung transplantation. Chest 124(5):1682-1688
43. Perry P, Zelimann C, Arndt S (1994) Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14(4):230-240
44. Politi P, Piccinelli M, Fusar-Poli P (2004) Ten years of "extended life": quality of life among heart transplant survivors. Transplantation 78:257-263
45. Rasmussen S, Overo K, Tanghoj P (1999) Cardiac safety of citalopram: prospective trials and retrospective analysis. J Clin Psychopharmacol 19(5):407-415
46. Rodrigue JR, Pearman TP, Moreb J (1999) Morbidity and mortality following bone marrow transplantation: predictive utility of pre-BMT affective functioning, compliance, and social support stability. Int J Behav Med 6(3):241-254
47. Rodrigue JR, Baz MA, Kanasky WF Jr, MacNaughton KL (2005) Does lung transplantation improve health-related quality of life? The University of Florida Experience. J Heart Lung Transplant 24(6):755-763
48. Roose S (2001) Depression, anxiety and the cardiovascular system: the psychiatrist's perspective. J Clin Psychiatry 62(Suppl 8):19-22
49. Ruschitzka F, Meier P, Turina M, et al. (2000) Acute heart transplant rejection due to St. John's wort. Lancet 355:548-549
50. Silvertooth EJ, Doraiswamy PM, Clary GL, et al. (2004) Citalopram and quality of life in lung transplant recipients. Psychosomatics 45(3):271-272
51. Singer HK, Ruchinskas RA, Riley KC, Broshek DK, Barth JT (2001) The psychological impact of end-stage lung disease. Chest 120(4):1246-1252
52. Smoller JW, Pollack MH, Otto MW, Rosenbaum JF, Kradin RL (1996) Panic anxiety, dyspnea, and respiratory disease. Theoretical and clinical considerations. Am J Respir Crit Care Med 154(1):6-17
53. Smoller JW, Simon NM, Pollack MH, Kradin R, Stern T (1999) Anxiety in patients with pulmonary disease: comorbidity and treatment. Semin Clin Neuropsychiatry 4(2):84-97
54. Squier H, Ries A, Kaplan R (1995) Quality of well-being predicts survival in lung transplantation candidates. Am J Respir Crit Care Med 152:2032-2036
55. Sredl D, Werner T, Springhart D, et al. (2003) An evidence-based pilot study exploring relationships between psychologic and physiologic factors in post-lung-transplant adolescents with cystic fibrosis. J Pediatr Nurs 18(3):216-220
56. Stilley CS, Dew MA, Stukas AA, et al. (1999) Psychological symptom levels and their correlates in lung and heart-lung transplant recipients. Psychosomatics 40(6):503-509
57. Taylor D, Leah B, Mark M (2004) The registry of the International Society of Heart and Lung Transplantation: twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 23:796-80
58. Teichman BJ, Burker EJ, Weiner M, Egan TM (2000) Factors associated with adherence to treatment regimens after lung transplantation. Prog Transplant 10(2):113-121
59. TenVergert EM, Essink-Bot ML, Geertsma A, et al. (1998) The effect of lung transplantation on health-related quality of life: a longitudinal study. Chest 113(2):358-364
60. Triffaux J, Wauthy J, Bertrand J (2001) Psychological evolution and assessment in patients undergoing orthotopic heart transplantation. Eur Psychiatry 16:180-185
61. Trzepacz P, Levenson J, Tringali R (1991) Psychopharmacology and neuropsychiatric syndromes in organ transplantation. Gen Hosp Psychiatry 13:233-245
62. van Den BJ, Geertsma A, van Der BW, et al. (2000) Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med 161(6):1937-1941
63. Vasiliadis HM, Collet JP, Poirier C (2006) Health-related quality-of-life determinants in lung transplantation. J Heart Lung Transplant 25(2):226-233
64. Vermeulen KM, Ouwens JP, van der Bij W, et al. (2003) Long-term quality of life in patients surviving at least 55 months after lung transplantation. Gen Hosp Psychiatry 25(2):95-102
65. Vermeulen KM, Groen H, van der Bij W, et al. (2004) The effect of bronchiolitis obliterans syndrome on health related quality of life. Clin Transplant 18(4):377-383
66. Vermeulen KM, van der Bij W, Erasmus ME, et al. (2004) Improved quality of life after lung transplantation in individuals with cystic fibrosis. Pediatr Pulmonol 37(5):419-426
67. Wilson KC, Saukkonen JJ (2004) Acute respiratory failure from abused substances. J Intensive Care Med 19(4):183-193
68. Woodman CL, Geist LJ, Vance S, et al. (1999) Psychiatric disorders and survival after lung transplantation. Psychosomatics 40(4):293-297
69. Wright D, Lake K, Bruhn P (1999) Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplant 18:913-915
70. Wu C, Benet L, Hebert M (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492-497